Early Eculizumab Withdrawal in Patients With Atypical Hemolytic Uremic Syndrome in Native Kidneys Is Safe and Cost-Effective: Results of the CUREiHUS Study

R.N. Bouwmeester,C. Duineveld,K.L. Wijnsma, F.J. Bemelman, J.W. van der Heijden, J.A.E. van Wijk,A.H.M. Bouts,J. van de Wetering,E. Dorresteijn,S.P. Berger,V. Gracchi,A.D. van Zuilen,M.G. Keijzer-Veen,A.P.J. de Vries, R.W.G. van Rooij, F.A.P.T. Engels, W. Altena, R. de Wildt, E. van Kempen, E.M. Adang,M. ter Avest,R. ter Heine,E.B. Volokhina,L.P.W.J. van den Heuvel,J.F.M. Wetzels,N.C.A.J. van de Kar

Kidney International Reports（2023）

引用 10|浏览17

暂无评分

摘要

It is safe and cost-effective to discontinue eculizumab after 3 months of therapy in patients with aHUS in native kidneys. Larger data registries are needed to determine factors associated with suboptimal kidney function recovery during eculizumab treatment, factors to predict relapses, and long-term outcomes of eculizumab discontinuation.

查看译文

关键词

atypical hemolytic uremic syndrome,complement,complement inhibition,cost-effectiveness,eculizumab,thrombotic microangiopathy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要